Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Recombinant anti-BDCA2 humanized monoclonal antibody(Sunshine Guojian) in Systemic Lupus Erythematosus: NCT07185269 Clinical Landscape Report 2026
15 October 2026
NCT07185269 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Teriflunomide in Multiple Sclerosis, Relapsing-Remitting: NCT07189325 Clinical Landscape Report 2026
15 October 2026
NCT07189325 clinical landscape for Multiple Sclerosis, Relapsing-Remitting: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Difamilast in Dermatitis, Atopic: NCT07184645 Clinical Landscape Report 2026
15 October 2026
NCT07184645 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Venetoclax in Acute Promyelocytic Leukemia: NCT07187505 Clinical Landscape Report 2026
15 October 2026
NCT07187505 clinical landscape for Acute Promyelocytic Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Relapse multiple myeloma: NCT07191379 Clinical Landscape Report 2026
15 October 2026
NCT07191379 clinical landscape for Relapse multiple myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Filgrastim (Amgen) in Hodgkin's Lymphoma: NCT07188090 Clinical Landscape Report 2026
15 October 2026
NCT07188090 clinical landscape for Hodgkin's Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
PF-08049820 in Dermatitis, Atopic: NCT07190430 Clinical Landscape Report 2026
15 October 2026
NCT07190430 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BCMA-GPRC5D CAR-T Cells(Guangzhou Bio-gene Technology) in Multiple Myeloma: NCT07195617 Clinical Landscape Report 2026
15 October 2026
NCT07195617 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CC-312 in Idiopathic Inflammatory Myopathies: NCT07193810 Clinical Landscape Report 2026
15 October 2026
NCT07193810 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Mitomycin in Carcinoma in situ of bladder: NCT07189793 Clinical Landscape Report 2026
15 October 2026
NCT07189793 clinical landscape for Carcinoma in situ of bladder: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ZL-82 in Dermatitis, Atopic: NCT07193589 Clinical Landscape Report 2026
15 October 2026
NCT07193589 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19 CAR-T cells(ShenZhen Cell Valley) in Scleroderma, Diffuse: NCT07193667 Clinical Landscape Report 2026
15 October 2026
NCT07193667 clinical landscape for Scleroderma, Diffuse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.